ANDA 215406, held by Amneal Pharmaceuticals. Nicardipine Hydrochloride.
As of Nov 22, 2026, ANDA 215406 (Nicardipine Hydrochloride), held by Amneal Pharmaceuticals, was first approved by FDA on Oct 31, 2024, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nicardipine Hydrochloride25MG/10ML (2.5MG/ML) · injectable;injection | Nicardipine Hydrochloride | Discontinued |
| Mar 6, 2026 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 31, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters